GH Research PLC

NASDAQ:GHRS

Biotechnology

Healthcare
$18.25 -0.18%

-$0.04 today

Market cap
$1.25B
Beta
1.31
P/E (TTM)
-23.8
EPS (TTM)
-$0.91
52W Low $11.32High $25.94

Volume 0.46M

Average 0.23M

GHRS Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

GH Research PLCNASDAQ: GHRS

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 62.03M shares rose 6.9% year over year, behind the +15.9% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +5.5% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +6.9% toward the trailing-twelve-month pace of +15.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
62.03M+0.0% QoQ
Last fiscal yearDec 2025
61.04M+17.3% YoY
LTMMar 2026
62.03M+15.9% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.9%——
1 year+17.3%——
3-year CAGR+5.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
61.04M USD
Year-over-year change
+17.3%
4-year CAGR
+4.1%

Weighted Avg Shares vs competitors

How GHRS compares with its peers on the latest reported figures

  • GHRS's LTM Mar 2026 weighted avg shares of 62.03M shares is the 4th highest of the 9 companies compared; the peer median is 42.47M shares.
  • Its year-over-year change of +15.9% is the 5th highest of 8, against a peer median of +30.7%.
  • Over three fiscal years its annual growth of +5.5% compares with a peer median of +24.6%.
GHRS Competitors Peer median
Weighted Avg Shares for GHRS and competitors
Company Period LTM YoY 3-year CAGR
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026166.7M +4.0%+2.4%
BHVNBiohaven Ltd.LTM Jun 2026131.06M +31.1%+34.0%
DFTXDefinium Therapeutics, Inc.LTM Sep 2026111.19M +30.7%+42.5%
GHRSGH Research PLCLTM Mar 202662.03M +15.9%+5.5%
MPLTMapLight Therapeutics, Inc.LTM Mar 202643.04M +3.9%+2.0%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 202641.9M +115.2%+32.7%
ANROAlto Neuroscience, Inc.LTM Mar 202629.75M +10.2%+4.1%
NERVMinerva Neurosciences, Inc.LTM Jun 202627.3M +260.6%+16.6%
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 202619.77M —+92.6%
SPTXSeaport Therapeutics, Inc. Common Stock—— ——
Peer median (excluding GHRS) 42.47M+30.7%+24.6%

Competitors are the stored peer set for GHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000335K
Gross Profit0000(335K)
Gross Margin—————
Research & Development8.55M20.48M29.82M35.02M38.73M
Selling, General & Admin6.54M10.06M11.12M15M21.61M
Operating Expenses15.1M30.55M41.22M50.31M60.34M
Depreciation & Amortization19K47K315K315K335K
EBITDA(9.17M)(22.41M)(35.21M)(38.6M)(47.46M)
EBITDA Margin—————
Operating Income(15.1M)(30.55M)(41.22M)(50.31M)(60.68M)
Operating Margin—————
Interest Income9858K1.89M2.63M2.63M
Interest Expense9K—723K717K463K
Other Income / Expenses5.9M8.1M5.64M11.35M12.42M
Income Before Tax(9.2M)(22.46M)(35.59M)(38.96M)(48.26M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(9.2M)(22.46M)(35.59M)(38.96M)(48.26M)
Net Margin—————
EPS (Basic)(0.18)(0.14)(0.68)(0.75)(0.79)
EPS (Diluted)(0.18)(0.14)(0.68)(0.75)(0.79)
Weighted Avg Shares52.02M52.02M52.02M52.03M61.04M
Weighted Avg Shares (Diluted)52.02M52.02M52.02M52.03M61.04M

GH Research PLC

NASDAQ:GHRS

Intrinsic Alpha fair value

Locked

Current Price

$18.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.